Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...
An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...
18h
Hosted on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...
Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Enveda gets support from Sanofi to advance AI-driven drug discovery to clinical trials: Boulder, Colorado Friday, February 28, 2025, 16:00 Hrs [IST] Enveda, a leading biotechnolog ...
Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.
4d
GlobalData on MSNSanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...
Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results